Investor Relations

Reshema Kemps-Polanco is Executive Vice President and Chief Commercial Officer of Novartis US, the U.S. operations of global biopharmaceutical company, Novartis AG. In this role, she is responsible for the end-to-end commercialization across four therapeutic areas, including oncology, immunology, neurology, and cardiovascular/renal/metabolic conditions. With 25 years of pharmaceutical industry experience, Ms. Kemps-Polanco has extensive healthcare business leadership knowledge and sales and marketing expertise, and a demonstrated ability to oversee large commercial organizations across multiple therapeutic areas. Prior to rejoining Novartis in 2021, Ms. Kemps-Polanco held several leadership positions at Johnson & Johnson from 2014 until 2021, most recently serving as President, Janssen U.S. Cardiovascular & Metabolism and Janssen Pharmaceuticals Puerto Rico, where she was responsible for developing and delivering the business strategy and driving the growth initiatives for these businesses. Ms. Kemps-Polanco began her career at Novartis in sales and held management positions of increasing responsibility, including leading the U.S. commercial team’s marketing strategy for its leukemia franchise and as U.S. brand leader for its osteoporosis therapy. She is a board member of the Healthcare Leadership Council (HLC), a coalition of chief executives focused on policies that make quality healthcare accessible to all Americans, a member of the Healthcare Businesswomen’s Association (HBA) Global Advisory Board, and the CEO Roundtable on Cancer. Ms. Kemps-Polanco has been a board member since January 2024.